It's paradigm shift time ranger. Technosphere will revolutionize drug delivery. Not trying to change your mind because I can appreciate your position. I just happen to think you're wrong. If nothing more there will be a run up in the stock prior to pdufa in April. Good luck to you.
My records reflect about 24 million shares changed hands on 11/11-11/12, then, a few days before TDay, 11/26-27 about 18 million shares pumped it from the .80's to $1.40 where it stayed for a very short hour or so. Do the match and you will see ZLCS is down about 5 million shares from 11/8.
If I did not sell on 11/11 and was sitting on some huge gains in other stocks that I want to sell, which I am not because I think they remain winners, then, if I did not bail on 11/11 I would be bailing this month. The market is open on the 30th, so, by then I would know if there any wheat left from the chaff.
I would not touch ZLCS unless it fell to .50, or less. The fundamentals and technicals are terrible.
The stock is consolidating at its current price and is now not over-sold or over-bought. IMO, if you have to buy this garbage, don't pull the trigger until it falls sub .85.
Now, if some new money came into the company, not in the stock which is quite different, then I would keep an eye on it and may try to make back the money I lost for a quick trade. I do not trust the company.
Take a look at SNTA, SGYP, (scary, but the charts are much-much better than ZLCS), VNDA and HPTX. Good upside on the first two if they pop, the latter two are 1/2 as good.
All of the biopharmas are nothing more than a #$%$-shot, but, to reiterate, ZLCS is on the very bottom. I do not see much potential. Too many flops the last year.
Maybe if Sanofi gets moving on Big Red next year, but from what I have read that won's happen until 2015.
There is just too much other opportunities in the market than to let it sit on dead stocks. Take a look at GILD id you want some pharma exposure. Better yet, look at EPL and HAL, a couple oil stocks which are down a lot and IMO will pop soon; $24 for EPL $48 for HAL would be a good buy in, but still a tad above support levels.
Someone mentioned IOC on this board. That could be a good play and a hell of a lot better than ZLCS.
Well, I've had some hard knocks, especially with Z, but I've never felt this good about my biotech portfolio....(especially today...lol)... FWIW:
MACK-- the next JAZZ...
CYTR-- will run like ACAD
NWBO-- I still believe
Good luck to all here. I will definitely re-enter Z in the future for Z944
I thought about pulling the trigger at 3.36. I'm watching to see if that would have been a mistake.... it'll probably go up from there since I didn't buy. lol
Chevelle, Yesterday I would have said it was close... this "event" drive selloff throws a monkey wrench in the works....
Terry, thanks for the thought ... I gots some chewing on stratagies(sp) to do..
Jim, my guess is that any source of cash will come with dilution - likely issuing of stock in exchange for cash. So, the stock increase will be diminished depending on how much dilution goes along with the cash infusion.
This may be the right time to buy NWBO while it's down. NWBO's methodology is different from IMUC, and by all reported evidence, it works well. If I had extra money, I would be pouring it in. The warrants have also gone down considerably. You should consider them, too. When this stock or warrant begins going back up you will make a fortune. These events are likely to show well before INOs.
Ruz: I wonder if the "2nd half" deal is technical or was it do to the belief that they would need to focus the cash on the next Z-160 Phase? If it was the cash they may be accelerating the time line???
The most desirable insider info would be the knowledge that they had found a source of cash infusion. If they find some the old girl will soar.
Jim Still calm
That's probably about right, slugger. I think this is as good a timeline as we're going to get - from Jason: "Our next steps are to evaluate Z944 in a modified release formulation in healthy volunteers and then we are planning to initiate a phase 2 study in an appropriate pain indication in the US in the second half of 2014."
I would say less - at least until Zalicus tells us what their timeline for Z944 is. Considering their cash-flow issues, a time-line is especially vital. Running out of cash before completing Phase 2 would be... a bummer.
any buy around $1 should be a good entry point, as IMHO someone is not going to let the stock going under $1 in order to avoid delisting, and you are in a good position to profit from any bounce up